Authors

Latest:

Dr. Uesaka on Gemcitabine vs S-1 in Pancreatic Cancer

Katsuhiko Uesaka, MD, PhD, from the Shizuoka Cancer Center Hospital in Japan, discusses the JASPAC-01 study that compared gemcitabine to S-1 in Asian patients with resected pancreatic cancer.

Kaushal Parikh, MD, MBBS

Latest:

Dr Parikh on the Impact of the ADAURA and ALINA Trials on Early-Stage NSCLC Management

Kaushal Parikh, MBBS, discusses how data from the ADAURA and ALINA trials have advanced the management of early-stage non–small cell lung cancer.

Kavita Patel, MD, MS

Latest:

Dr. Patel Discusses the Cancer Drug Coverage Parity Act

Kavita Patel, MD, MS, policy analyst, Brookings Institution, discusses the Cancer Drug Coverage Parity Act.

Kavitha Ramchandran, MD

Latest:

Dr. Ramchandran on Considerations for Palliative Care in Thoracic Cancers

Kavitha Ramchandran, MD, discusses considerations as patients with thoracic malignancies enter palliative care.

Kazuhiko Nakagawa, MD, PhD

Latest:

Dr. Nagawaka Discusses Findings of the RELAY Trial in EGFR+ NSCLC

Kazuhiko Nakagawa, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan, discusses findings of the RELAY trial in EGFR-positive non–small cell lung cancer.

Kebede H. Begna, MD

Latest:

Dr. Begna on Recent Advancements in MPNs

Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

Keerthi Gogineni, MD

Latest:

Dr. Gogineni on the Efficacy of CDK4/6 Inhibitors Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

Keerthi Gogineni, MD, MSHP, discusses the efficacy of CDK4/6 inhibitors plus endocrine therapy in patients with hormone receptor–positive, HER2-negative early breast cancer.

Keerthi Gogineni, MD, MSHP

Latest:

Dr. Gogineni on Implications of the APT Trial in HER2+ Breast Cancer

Keerthi Gogineni, MD, MSHP, discusses the clinical implications of the phase II APT trial in HER2-positive breast cancer.

Kei Muro, MD

Latest:

Dr. Muro Discusses Safety Data from Asian XELIRI Project in CRC

Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).

Kei Muro, MD, Aichi Cancer Center Hospital

Latest:

Evidence-Based Treatment of Metastatic Gastric Cancer

Keith

Keith C. Bible, MD, PhD

Latest:

Dr. Bible on Impact of Lenvatinib on Treatment Landscape of DTC

Keith C. Bible, MD, PhD, medical oncologist, Mayo Clinic, discusses the impact that lenvatinib (Lenvima) has had on the treatment landscape of differentiated thyroid cancer.

Keith Kerr, BSc, MB ChB

Latest:

Dr. Kerr on Misconceptions With Molecular Profiling in Lung Cancer

Keith Kerr, BSc, MB, ChB, consultant pathologist, University of Aberdeen, Aberdeen, Scotland, discusses common misconceptions with molecular profiling in lung cancer.

Keith McCrae, MD, Cleveland Clinic

Keith R McCrae, MD, The Cleveland Clinic

Keith R. Unger, MD

Latest:

Dr. Unger on Utilizing a Multidisciplinary Team in Gastroesophageal Cancer

Keith R. Unger, MD, discusses utilizing a multidisciplinary team to treat patients with gastroesophageal cancer.

Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital

Latest:

Multiple Myeloma: Planning a Continuum of Care in 2020

Keith Stewart, MB, CHB, Mayo Clinic

Keith Stewart, MD, ChB, MBA, Mayo Clinic

Latest:

Investigational Agents for Relapsed/Refractory Myeloma

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.

Keith T. Flaherty, MD

Latest:

Dr. Flaherty on the Significance of the NCI-MATCH Precision Medicine Trial

Keith T. Flaherty, MD, discusses the significance of the NCI-MATCH study.